假体周围非典型股骨骨折存在且与双膦酸盐疗程相关
这项回顾性病例对照研究纳入2007至2017年间假体周围股骨骨折患者,识别出16例符合非典型股骨骨折标准的假体周围非典型股骨骨折(PAFF)和17例接受双膦酸盐治疗的典型假体周围骨折对照。多因素分析显示双膦酸盐疗程是PAFF的独立预测因素,PAFF后并发症率尤其是再手术和感染更高。
要点
- PAFF分类的观察者间一致性极好(kappa=0.944;p<0.001)。
- PAFF组双膦酸盐疗程中位5.5年 vs 对照组2.4年(p=0.04),疗程是独立预测因素(R2=0.733;p=0.05)。
- PAFF组任何并发症相对风险1.71(95%CI 0.77至3.8),再手术相对风险2.56(95%CI 1.3至5.2)。
核心结论
- 非典型股骨骨折确实可与假体相关发生,双膦酸盐疗程较长是PAFF的独立预测因素。
- PAFF后并发症率高于典型假体周围骨折,尤其是再手术和感染。
研究设计与样本
- 回顾性病例对照研究,纳入2007至2017年间连续假体周围股骨骨折患者。
- PAFF组16例(平均年龄73.9岁(44至88),14例女性),对照组17例接受双膦酸盐治疗的典型假体周围骨折(平均年龄80.7岁(60至86),13例女性)。
- 采用单因素和多因素分析识别PAFF预测因素,并记录处理与并发症。
主要发现
- PAFF分类观察者间一致性极好(kappa=0.944;p<0.001)。
- 单因素分析中,PAFF组较对照组平均体重指数更高(28.6 kg/m2(sd 8.9) vs 21.5 kg/m2(sd 3.3);p=0.009)。
- PAFF组双膦酸盐疗程中位更长(5.5年(IQR 3.2至10.6) vs 2.4年(IQR 1.0至6.4);p=0.04)。
- PAFF组使用阿仑膦酸盐比例更低(50% vs 94%;p=0.02),继发性骨质疏松适应证比例更高(19% vs 0%;p=0.049)。
- 多因素分析中双膦酸盐疗程是PAFF独立预测因素(R2=0.733;p=0.05)。
关键数值与推荐
- 初次骨折处理后,PAFF组并发症率9/16(56%) vs 对照组5/17(29%);p=0.178。
- PAFF后任何并发症相对风险1.71(95%CI 0.77至3.8),再手术相对风险2.56(95%CI 1.3至5.2)。
临床怎么用
- 对接受双膦酸盐治疗且发生假体周围股骨骨折的患者,应评估是否符合非典型股骨骨折标准。
- 较长双膦酸盐疗程与PAFF风险独立相关,需在评估中关注用药时长。
- PAFF后并发症和再手术风险较高,处理时应警惕感染和再手术可能。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Currently, periprosthetic fractures are excluded from the American Society for Bone and Mineral Research (ASBMR) definition of atypical femoral fracture (AFFs). This study aims to report on a series of periprosthetic femoral fractures (PFFs) that otherwise meet the criteria for AFFs. Secondary aims were to identify predictors of periprosthetic atypical femoral fractures (PAFFs) and quantify the complications of treatment. PATIENTS AND METHODS: This was a retrospective case control study of consecutive patients with periprosthetic femoral fractures between 2007 and 2017. Two observers identified 16 PAFF cases (mean age 73.9 years (44 to 88), 14 female patients) and 17 typical periprosthetic fractures in patients on bisphosphonate therapy as controls (mean age 80.7 years (60 to 86, 13 female patients). Univariate and multivariate analysis was performed to identify predictors of PAFF. Management and complications were recorded. RESULTS: Interobserver agreement for the PAFF classification was excellent (kappa = 0.944; p < 0.001). On univariate analysis compared with controls, patients with PAFFs had higher mean body mass indices (28.6 kg/m2 (sd 8.9) vs 21.5 kg/m2 (sd 3.3); p = 0.009), longer durations of bisphosphonate therapy (median 5.5 years (IQR 3.2 to 10.6) vs 2.4 years (IQR 1.0 to 6.4); p = 0.04), and were less likely to be on alendronate (50% vs 94%; p = 0.02) with an indication of secondary osteoporosis (19% vs 0%; p = 0.049). Duration of bisphosphonate therapy was an independent predictor of PAFF on multivariate analysis (R2 = 0.733; p = 0.05). Following primary fracture management, complication rates were higher in PAFFs (9/16, 56%) than controls (5/17, 29%; p = 0.178) with a relative risk of any complication following PAFF of 1.71 (95% confidence interval (CI) 0.77 to 3.8) and of reoperation 2.56 (95% CI 1.3 to 5.2). CONCLUSION: AFFs do occur in association with prostheses. Longer duration of bisphosphonate therapy is an independent predictor of PAFF. Complication rates are higher following PAFFs compared with typical PFFs, particularly of reoperation and infection. Cite this article: Bone Joint J 2019;101-B:1285-1291.
引用
- MacKenzie SA, Ng RT, Snowden G, et al. Periprosthetic atypical femoral fractures exist and are associated with duration of bisphosphonate therapy. Bone Joint J. 2019. PMID: 31564154. doi:10.1302/0301-620X.101B10.BJJ-2019-0599.R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。